Systemic bioavailability of estriol following single and repeated vaginal administration of 003 mg estriol containing pessaries

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 8, 2012, Pages 378-383

  Buhling, K J ^a   Eydeler, U ^b   Borregaard, S ^b   Schlegelmilch, R ^c   Suesskind, M ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MediGate GmbH   (Germany)

^c Dr Kade Pharmazeutische Fabrik GmbH   (Germany)

Author keywords

bioavailability; estriol; local treatment; low dose formulation; pharmacokinetic profile; vaginal atrophy

Indexed keywords

DIETHYLSTILBESTROL; ESTRIOL; OEKOLP OVULA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; REACTION TIME; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA PESSARY; VAGINA SWELLING;

ADMINISTRATION, INTRAVAGINAL; AGED; BIOLOGICAL AVAILABILITY; ESTRIOL; FEMALE; HUMANS; MIDDLE AGED; PESSARIES; PROSPECTIVE STUDIES;

EID: 84865616160     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1314822     Document Type: Article

References (34)

1. Stenberg A, Heimer G, Ulmsten U et al. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas: 1996; 24 1-2 31 36 (Pubitemid 26180101)
2. Raz R. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. J Infect Dis: 2001; 183 74 76
3. Dennerstein L, Dudley E C, Hopper J L et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol: 2000; 96 351 358
4. Trevoux R, Van der Velden W H, Popovic D. Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduction: 1982; 6 101 106 (Pubitemid 13241390)
5. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas: 1990; 12 171 197 (Pubitemid 20279929)
6. Clark J H, Markaverich B M. The agonistic and antagonistic effects of short acting estrogens: A review. Pharmac Ther: 1983; 21 429 453 (Pubitemid 13002640)
7. Cardozo L, Bachmann G, McClish D et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol: 1998; 92 722 727 (Pubitemid 28440818)
8. Suckling J A, Kennedy R, Lethaby A et al. Using creams, pessaries or a vaginal ring to apply oestrogen vaginally relieves the symptoms of vaginal atrophy, although some creams may cause adverse effects [cited 2010 Nov 10]. In: The Cochrane Database of Systemic Reviews [Internet]. Hoboken (NJ) John Wiley & Sons, Ltd Available from: http://summaries.cochrane.org/CD001500/using- creams-pessaries-or-a-vaginal-ring-to-apply-oestrogen-vaginally-relieves-the- symptoms-of-vaginal-atrophy-although-some-creams-may-cause-adverse-effects
9. The North American Menopause Society The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause: 2007; 14 355 363
10. Sturdee D W, Panay N. International Menopause Society Writing Group Recommendations for the management of postmenopausal vaginal atrophy. Climacteric: 2010; 13 509 522
11. AWMF online [Internet] Düsseldorf: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Record No. 015-062. Hormontherapie in der Peri- und Postmenopause; [cited 2009 Sep 1] Available from: http://www.awmf.org/leitlinien/detail/ll/015-062.html
12. Dessole S, Rubattu G, Ambrosini G et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause: 2004; 11 49 56 (Pubitemid 40362198)
13. Chuery A C, Speck N M, de Moura K F et al. Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. Clin Exp Obstet Gynecol: 2011; 38 143 145
14. Dugal R, Hesla K, Sordal T et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand: 2000; 79 293 297 (Pubitemid 30156501)
15. Barentsen R, van de Weijer P H, Schram J H. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol: 1997; 71 73 80 (Pubitemid 27045856)
16. Clocuh YP A. Oestrogengabe als hormonelle Aufhellung zur Abklärung atrophischer Zellabstriche. Geburtsh u Frauenheilk: 1980; 40 1121 1129
17. Bottiglione F, Volpe A, Esposito G et al. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas: 1995; 22 227 232
18. Biglia N, Peano E, Sgandurra P et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gyn Endocrinol: 2010; 26 06 404 412
19. Henrikkson L, Stjernquist M, Boquist L et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol: 1996; 174 85 92 (Pubitemid 26037694)
20. Sindberg Eriksen P, Rasmussen H. Low-dose 17β-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol: 1992; 44 137 144
21. th World Congress on the Menopause. Climacteric: 2011; 14 01 86
22. Griesser H, Skonietzki S, Fischer T et al. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas: 2012; 71 04 360 368
23. Fachinformation OeKolp® Ovula. Dr. Kade Pharmazeutische Fabrik GmbH; January: 2012
24. Feichter G. Vaginale Zytologie: Cervix uteri und Vagina. In: Feichter G, Dalquen P. (eds.). Pathologie Band 8: Zytopathologie. Berlin, Heidelberg, New York Springer-Verlag: 2000; 65
25. Klinge C M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res: 2001; 29 14 2905 2919 (Pubitemid 32685217)
26. Gitsch E, Golob E. Zur Frage der idealen Östrogenkonzentration in Salben bei genitaler Anwendung. Zbl Gynäkol: 1962; 12 454 458
27. Heimer G M, Englund D E. Effects of vaginally administered oestriol on postmenopausal urogenital disorders: a cytohormonal study. Maturitas: 1992; 14 171 179
28. Heimer G M, Englund D R. Plasma oestriol following vaginal administration: morning versus evening insertion and the influence of food. Maturitas: 1986; 8 239 243 (Pubitemid 17170490)
29. Magnusson C, Baron J A, Correia N et al. Breast-cancer risk following long-term estrogen- and estrogen-progestin replacement therapy. Int J Cancer: 1999; 81 339 344 (Pubitemid 29165190)
30. Vooijs G P, Geurts TB P. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol: 1995; 62 101 106
31. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol: 2006; 108 06 1354 1360 (Pubitemid 44901007)
32. Kaiser R, Michael-Hepp J, Weber W et al. Absorption of estriol from vaginal tablets after single and repeated application in healthy postmenopausal women. Therapiewoche: 2000; 16 03 1 8
33. Heimer G, Englund D. Estriol: Absorption after Long-Term Vaginal Treatment and Gastrointestinal Absorption as Influenced by a Meal. Acta Obstet Gynecol Scand: 1984; 63 563 567 (Pubitemid 14018207)
34. th World Congress on the Menopause. Climacteric: 2011; 14 01 66